References
- Agarwal R, D'Souza T, Morin PJ (2005). Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res, 65, 7378-85. https://doi.org/10.1158/0008-5472.CAN-05-1036
- Akbulut S (2012). Unusual cause of adult intussusception: diffuse large B-cell non-Hodgkin's lymphoma: a case report and review. Eur Rev Med Pharmacol Sci, 16, 1938.
- Bornfeldt KE, Raines EW, Graves LM, et al (1995). Plateletderived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci, 766, 416-30. https://doi.org/10.1111/j.1749-6632.1995.tb26691.x
- Cai W, Chen X (2006). Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem, 6, 407-28. https://doi.org/10.2174/187152006778226530
- Chen J, Xu X, Wang H (2009). Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion. J Huazhong Univ Sci Technolog Med Sci, 29, 94-6. https://doi.org/10.1007/s11596-009-0120-6
- Courtney KD, Corcoran RB, Engelman JA (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol, 28, 1075-83. https://doi.org/10.1200/JCO.2009.25.3641
- Davidson B, Elstrand MB, McMaster MT, et al (2005). HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol, 96, 42-7. https://doi.org/10.1016/j.ygyno.2004.09.049
- Davis FG, McCarthy BJ, Berger MS (1999). Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results;and National Cancer Data Base. Neuro Oncol, 1, 205-11.
- Davis RE, Ngo VN, Lenz G, et al (2010). Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92. https://doi.org/10.1038/nature08638
- Dhawan P, Singh AB, Deane NG, et al (2005). Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest, 115, 1765-76. https://doi.org/10.1172/JCI24543
- Hannigan G, Troussard AA, Dedhar S (2005). Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer, 5, 51-63. https://doi.org/10.1038/nrc1524
- Havenith MG, Arends JW, Simon R, et al (1988). Type IV collagen immunoreactivity in colorectal cancer. Prognostic value of basement membrane deposition. Cancer, 62, 2207-11. https://doi.org/10.1002/1097-0142(19881115)62:10<2207::AID-CNCR2820621023>3.0.CO;2-L
- Huang da W, Sherman BT, Lempicki RA (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 37, 1-13. https://doi.org/10.1093/nar/gkn923
- Iqbal J, Neppalli VT, Wright G, et al (2006). BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol, 24, 961-8. https://doi.org/10.1200/JCO.2005.03.4264
- Kakinuma T, Hwang ST (2006). Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol, 79, 639-51. https://doi.org/10.1189/jlb.1105633
- Katso R, Okkenhaug K, Ahmadi K, et al (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol, 17, 615-75. https://doi.org/10.1146/annurev.cellbio.17.1.615
- Kawano R, Ohshima K, Karube K, et al (2004). Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br J Haematol, 127, 305-7. https://doi.org/10.1111/j.1365-2141.2004.05197.x
- Klein RS, Rubin JB (2004). Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol, 25, 306-14. https://doi.org/10.1016/j.it.2004.04.002
- Koizumi K, Hojo S, Akashi T, et al (2007). Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci, 98, 1652-8. https://doi.org/10.1111/j.1349-7006.2007.00606.x
- Koutros S, Schumacher FR, Hayes RB, et al (2010). Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res, 70, 2389-96. https://doi.org/10.1158/0008-5472.CAN-09-3575
- Lenz G, Davis RE, Ngo VN, et al (2008). Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science, 319, 1676-9. https://doi.org/10.1126/science.1153629
- Lokker NA, Sullivan CM, Hollenbach SJ, et al (2002). Plateletderived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res, 62, 3729-35.
- Lossos IS, Jones CD, Warnke R, et al (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood, 98, 945-51. https://doi.org/10.1182/blood.V98.4.945
- Michl P, Buchholz M, Rolke M, et al (2001). Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology, 121, 678-84. https://doi.org/10.1053/gast.2001.27124
- Mitra SK, Schlaepfer DD (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol, 18, 516-23. https://doi.org/10.1016/j.ceb.2006.08.011
- Montesinos-Rongen M, Schafer E, Siebert R, Deckert M Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol, 124, 905-6.
- Monti S, Savage KJ, Kutok JL, et al (2005). Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 105, 1851-61. https://doi.org/10.1182/blood-2004-07-2947
- Morin PJ (2005). Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res, 65, 9603-6. https://doi.org/10.1158/0008-5472.CAN-05-2782
- Muniz LR, Pacer ME, Lira SA, Furtado GC A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J Immunol, 187, 828-34.
- Oikawa Y, Hansson J, Sasaki T, et al Melanoma cells produce multiple laminin isoforms and strongly migrate on alpha5 laminin(s) via several integrin receptors. Exp Cell Res, 317, 1119-33.
- Oku N, Sasabe E, Ueta E, et al (2006). Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res, 66, 5251-7. https://doi.org/10.1158/0008-5472.CAN-05-4478
- Rangel LB, Agarwal R, D'Souza T, et al (2003). Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res, 9, 2567-75.
- Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005). HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res, 65, 10139-44. https://doi.org/10.1158/0008-5472.CAN-05-0097
- Smith JR, Falkenhagen KM, Coupland SE, et al (2007). Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol, 127, 633-41. https://doi.org/10.1309/NUQHJ79BHWYD9TAF
- Sung CO, Kim SC, Karnan S, et al (2011). Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood, 117, 1291-300. https://doi.org/10.1182/blood-2010-07-297861
- Takehara M, Nishimura T, Mima S, et al (2009). Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biol Pharm Bull, 32, 825-31. https://doi.org/10.1248/bpb.32.825
- Wee S, Lengauer C, Wiederschain D (2008). Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis:implications for cancer drug discovery and development. Curr Opin Oncol, 20, 77-82. https://doi.org/10.1097/CCO.0b013e3282f3111e
- Xu Y, Liu L, Qiu X, et al CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. PLoS One, 6, e21119.
- Yao WK, Wang YP, Peng F, et al (2012). [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi, 41, 818-22.